Macrophage Activation Markers in COVID-19 Patients

Is the Severity of COVID-19 in Obese and Diabetic Patients Linked to High Serum Levels of MMP-7, MMP-9, TGF-β and PDGF Macrophage Activation Markers?

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04766294

Acronym

COVID-19

Enrollment

Registered

2021-02-23

Start date

2020-04-25

Completion date

2021-04-01

Last updated

2021-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

This study is aiming to find the relation between the severity of COVID-19 in diabetic and obese patients and the high serum levels of matrix metalloproteinase-7 (MMP-7),matrix metalloproteinase-9 (MMP-9), TGF-β and PDGF Macrophage Activation Markers

Detailed description

Acute respiratory distress syndrome (ARDS) commonly occurs in COVID-19 patients who are diabetic and obese, ARDS is characterized by inflammation and pulmonary fibrosis mediated by cytokines and biomarkers released from activated alveolar macrophages, also cytokine storm may occurs leading to multiple organ failure. These sequelae of COVID-19 disease in obese and diabetic patients are attributed to elevated plasma lipopolysaccharide which is the main activator of M1 and M2 macrophages. chronic activation of macrophages leads to production of profibrotic markers as transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF), matrix metalloproteinase-7 (MMP7) and matrix metalloproteinase-9 (MMP9) which promote fibrogenesis. In this research, we measure circulatory alveolar macrophage activation markers in COVID-19 obese patients with type 1 and type 2 diabetes.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

19 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Overweight patients with body mass index higher than 25 and obese patients with body mass index higher than 30 were selected to be included * Type one and type two diabetes mellitus patients were also included

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Measurement of matrix metalloproteinase-7 MMP-7 serum level (pg/ml) as a biomarker of macrophage activation	MMP-7 is measured after admission of patients to isolation hospital along 7 days interval for 21 days, 3 plasma samples are collected on the 7th day of admission, day 14 and day 21	ELISA Enzyme linked immunosorbent assay technique.
Measurement of matrix metalloproteinase-9 MMP-9 serum level (pg/L) as a biomarker of macrophage activation	MMP-9 is measured after admission of patients to isolation hospital along 7 days interval for 21 days, 3 plasma samples are collected on the 7th day of admission, day 14 and day 21	ELISA Enzyme linked immunosorbent assay technique.
Measurement of transforming growth factor B TGF-B serum level ( pg/ml) as a biomarker of macrophage activation	TGF-B is measured after admission of patients to isolation hospital along 7 days interval for 21 days, 3 plasma samples are collected on the 7th day of admission, day 14 and day 21	ELISA Enzyme linked immunosorbent assay technique.
Measurement of platelet derived growth factor PDGF serum level (ng/ml) as a biomarker of macrophage activation	PDGF is measured after admission of patients to isolation hospital along 7 days interval for 21 days, 3 plasma samples are collected on the 7th day of admission, day 14 and day 21	ELISA Enzyme linked immunosorbent assay technique.

Countries

Egypt

Outcome results